Dr. Reddy’s Laboratories (NYSE:RDY) Shares Gap Up – Here’s What Happened

Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s share price gapped up prior to trading on Monday . The stock had previously closed at $12.68, but opened at $13.20. Dr. Reddy’s Laboratories shares last traded at $13.19, with a volume of 99,105 shares trading hands.

Analysts Set New Price Targets

RDY has been the subject of a number of research reports. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Trading Up 4.1 %

The business’s 50-day moving average is $13.87 and its two-hundred day moving average is $14.79. The stock has a market capitalization of $11.02 billion, a PE ratio of 21.03 and a beta of 0.48. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of RDY. OneDigital Investment Advisors LLC purchased a new stake in shares of Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $277,000. Natixis Advisors LLC boosted its stake in shares of Dr. Reddy’s Laboratories by 7.2% during the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock worth $869,000 after purchasing an additional 735 shares during the last quarter. Caprock Group LLC raised its position in shares of Dr. Reddy’s Laboratories by 17.7% in the third quarter. Caprock Group LLC now owns 15,398 shares of the company’s stock valued at $1,223,000 after buying an additional 2,318 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Dr. Reddy’s Laboratories during the third quarter valued at approximately $1,997,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Dr. Reddy’s Laboratories by 219.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock worth $12,353,000 after acquiring an additional 106,796 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.